Article

The treatment of glioblastomas (GBMs) has changed significantly
since 2005. However, the extent to which this change has improved overall
survival (OS) of patients treated outside clinical trials remains to be
determined. METHODS: We compared the patterns of care and OS of all GBM patients
diagnosed in 2004 (n=105) and in 2008 (n=130) in our center. RESULTS: Younger
patients (aged<70 years) diagnosed in 2008 received temozolomide
radiochemotherapy as the initial treatment and bevacizumab at recurrence more
frequently than those diagnosed in 2004 (69% vs 26% P<10(-4) and 41% vs 3%,
P<10(-4), respectively). Elderly patients (aged>/=70 years) diagnosed in 2008
received an oncological treatment (radiotherapy and/or chemotherapy) more
frequently than those diagnosed in 2004 (67% vs 38%, P=0.006). The patients
diagnosed in 2008 had longer OS than those diagnosed in 2004 (10.5 months vs 5.3
months, P=0.001). This finding was true for both younger and elderly patients
(15.3 months vs 8.9 months, P=0.02 and 6.4 months vs 3.2 months, P=0.0002,
respectively) and when considering only IDH1 wild-type patients (8.9 months vs
5.3 months, P=0.004). CONCLUSION: In our center, the change in the patterns of
care for GBMs between 2004 and 2008 has been associated with a significant
improvement in OS.
CI - Copyright (c) 2014 Elsevier Masson SAS. All rights reserved.
- Tumeur - Cancer

Langue : ANGLAIS